AngioDynamics Inc has a consensus price target of $17, established from looking at the 17 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, Raymond James, and HC Wainwright & Co. on April 5, 2024, January 9, 2024, and January 8, 2024. With an average price target of $13.33 between Oppenheimer, Raymond James, and HC Wainwright & Co., there's an implied 127.14% upside for AngioDynamics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
04/05/2024 | ANGO | Buy Now | AngioDynamics | $5.87 | 104.43% | Oppenheimer | Steven Lichtman | → $12 | Upgrade | Perform → Outperform | Get Alert |
01/09/2024 | ANGO | Buy Now | AngioDynamics | $5.87 | 70.36% | Raymond James | Jayson Bedford | $12 → $10 | Maintains | Outperform | Get Alert |
01/08/2024 | ANGO | Buy Now | AngioDynamics | $5.87 | 206.64% | HC Wainwright & Co. | Yi Chen | $20 → $18 | Maintains | Buy | Get Alert |
10/06/2023 | ANGO | Buy Now | AngioDynamics | $5.87 | 104.43% | Raymond James | Jayson Bedford | $13 → $12 | Maintains | Outperform | Get Alert |
10/05/2023 | ANGO | Buy Now | AngioDynamics | $5.87 | 189.61% | Canaccord Genuity | William Plovanic | $20 → $17 | Maintains | Buy | Get Alert |
10/05/2023 | ANGO | Buy Now | AngioDynamics | $5.87 | 240.72% | HC Wainwright & Co. | Yi Chen | $19 → $20 | Maintains | Buy | Get Alert |
09/25/2023 | ANGO | Buy Now | AngioDynamics | $5.87 | 223.68% | HC Wainwright & Co. | Yi Chen | → $19 | Initiates | → Buy | Get Alert |
07/13/2023 | ANGO | Buy Now | AngioDynamics | $5.87 | 240.72% | Canaccord Genuity | William Plovanic | $18 → $20 | Maintains | Buy | Get Alert |
04/17/2023 | ANGO | Buy Now | AngioDynamics | $5.87 | 121.47% | Raymond James | Jayson Bedford | $14 → $13 | Downgrade | Strong Buy → Outperform | Get Alert |
04/03/2023 | ANGO | Buy Now | AngioDynamics | $5.87 | 138.5% | Raymond James | Jayson Bedford | $22 → $14 | Maintains | Strong Buy | Get Alert |
01/06/2023 | ANGO | Buy Now | AngioDynamics | $5.87 | 274.79% | Raymond James | Jayson Bedford | $25 → $22 | Maintains | Strong Buy | Get Alert |
10/07/2022 | ANGO | Buy Now | AngioDynamics | $5.87 | 325.89% | Raymond James | Jayson Bedford | $27 → $25 | Maintains | Strong Buy | Get Alert |
07/13/2022 | ANGO | Buy Now | AngioDynamics | $5.87 | 359.97% | Raymond James | Jayson Bedford | $32 → $27 | Maintains | Strong Buy | Get Alert |
10/15/2021 | ANGO | Buy Now | AngioDynamics | $5.87 | 530.32% | Canaccord Genuity | William Plovanic | — | Upgrade | Hold → Buy | Get Alert |
08/20/2021 | ANGO | Buy Now | AngioDynamics | $5.87 | — | Oppenheimer | Steven Lichtman | — | Initiates | → Perform | Get Alert |
07/14/2021 | ANGO | Buy Now | AngioDynamics | $5.87 | 377% | Canaccord Genuity | — | — | Maintains | Hold | Get Alert |
07/09/2021 | ANGO | Buy Now | AngioDynamics | $5.87 | 445.14% | Raymond James | Jayson Bedford | — | Maintains | Strong Buy | Get Alert |
The latest price target for AngioDynamics (NASDAQ: ANGO) was reported by Oppenheimer on April 5, 2024. The analyst firm set a price target for $12.00 expecting ANGO to rise to within 12 months (a possible 104.43% upside). 8 analyst firms have reported ratings in the last year.
The latest analyst rating for AngioDynamics (NASDAQ: ANGO) was provided by Oppenheimer, and AngioDynamics upgraded their outperform rating.
The last upgrade for AngioDynamics Inc happened on April 5, 2024 when Oppenheimer raised their price target to $12. Oppenheimer previously had a perform for AngioDynamics Inc.
The last downgrade for AngioDynamics Inc happened on April 17, 2023 when Raymond James changed their price target from $14 to $13 for AngioDynamics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AngioDynamics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AngioDynamics was filed on April 5, 2024 so you should expect the next rating to be made available sometime around April 5, 2025.
While ratings are subjective and will change, the latest AngioDynamics (ANGO) rating was a upgraded with a price target of $0.00 to $12.00. The current price AngioDynamics (ANGO) is trading at is $5.87, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.